Comparative Efficacy of Medical Treatments for Thyroid Eye Disease: A Network Meta-Analysis
Authors:
Open Access
- 12 December 2018
- journal article
- review article
- Published by Wiley in Journal of Ophthalmology
- Vol. 2018, 1-10
Abstract
Purpose. Numerous medical strategies have been proposed for the treatment of thyroid eye disease (TED); however, the best methods for standard treatment are still a matter of controversy. The purpose of this network meta-analysis was to integrate previous evidence to create hierarchies of comparative efficacy of eleven commonly used medical treatments for TED. Methods. A comprehensive search of electronic scientific literature databases was performed and the data from randomized controlled trials (RCTs) comparing treatment outcomes for patients with active TED were selected. Treatment strategies included in this network meta-analysis were intravenous glucocorticoids (IVGC), oral glucocorticoids (OGC), orbital injection of glucocorticoids (OIGC), orbital radiotherapy (OR), intravenous glucocorticoids combined with orbital radiotherapy (IVGC + OR), oral glucocorticoids combined with orbital radiotherapy (OGC + OR), rituximab (RTX), somatostatin analogs, intravenous immunoglobulin (IVIG), teprotumumab, and cyclosporine. The outcomes were response rate, mean difference in proptosis reduction, and reduction in disease activity. A random-effects network meta-analysis using a frequent method was conducted in STATA. Results. Twenty-three studies comprising a total of 1047 patients were included in the analysis. Inconsistency plots showed heterogeneity in the IVGC-Placebo-RTX loop to some extent (RoR = 8.029, ). Rankings of response rates were as follows: IVGC + OR, teprotumumab, IVGC, OGC + OR, RTX, OIGC, OR, IVIG, OGC, somatostatin, placebo, and cyclosporine. The rank probability analysis of proptosis reduction showed that teprotumumab was the most effective, followed by IVGC, IVGC + OR, OIGC, OGC, OGC + OR, OR, somatostatin, cyclosporine, and placebo. Conclusions. IVGC, alone or combination with OR, and teprotumumab should be preferred as the most effective strategies for active moderate to severe TED. Teprotumumab showed profound effect on proptosis reduction. OIGC, OR, and somatostatin analogs showed some statistical benefit and can be employed as second-line treatment strategies. RTX is a promising biologic agent, but more RCTs are required to define its appropriate role in treating TED.
Keywords
Funding Information
- Youth Research Foundation of Fujian Provincial Health and Family Planning Commission (2015-1-10, 2017XQ1022, 2018J01238)
- Startup Fund for Scientific Research of Fujian Medical University (2015-1-10, 2017XQ1022, 2018J01238)
- Fujian Provincial Natural Science Foundation (2015-1-10, 2017XQ1022, 2018J01238)
This publication has 48 references indexed in Scilit:
- Plasma filtration in the treatment of graves' ophthalmopathy: A randomized studyJournal of Clinical Apheresis, 2010
- Orbital steroid injection versus oral steroid therapy in management of thyroid‐related ophthalmopathyClinical & Experimental Ophthalmology, 2010
- Repeated peribulbar injections of triamcinolone acetonide: a successful and safe treatment for moderate to severe Graves’ ophthalmopathyActa Ophthalmologica, 2009
- Orbital Radiation for Graves OphthalmopathyOphthalmology, 2008
- Treatment of thyroid associated ophthalmopathy with periocular injections of triamcinoloneBritish Journal of Ophthalmology, 2004
- A long-term follow-up study after retro-orbital irradiation for graves’ ophthalmopathyInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2002
- The Effect of Somatostatin versus Corticosteroid in the Treatment of Graves' OphthalmopathyThyroid®, 1996
- Age and gender influence the severity of thyroid‐associated ophthalmopathy: a study of 101 patients attending a combined thyroid‐eye clinicClinical Endocrinology, 1993
- Prednisone and Cyclosporine in the Treatment of Severe Graves' OphthalmopathyNew England Journal of Medicine, 1989
- Ciclosporin and prednisone v. prednisone in treatment of Graves' ophthalmopathy: a controlled, randomized and prospective studyEuropean Journal of Clinical Investigation, 1986